ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.69+0.04 (+1.10%)
Close on Nov 18, 2026Market cap $366.96MP/E –Yield –
ARS Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
ARS Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$196.60M. For fiscal 2025 it was -$171.21M, down 1418.5% from the year before. The highest annual figure on record is $12.99M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$171.21M | -1418.5% |
| FY2024 | Dec 31, 2024 | $12.99M | – |
| FY2023 | Dec 31, 2023 | -$59.44M | – |
| FY2022 | Dec 31, 2022 | -$40.28M | – |
| FY2021 | Dec 31, 2021 | -$17.62M | – |
| FY2020 | Dec 31, 2020 | -$32.11M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$60.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$43.49M | -204.3% |
| Q3 FY2025 | Sep 30, 2025 | -$47.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$40.83M | – |
| Q4 FY2024 | Dec 31, 2024 | $41.70M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.62M | -172.0% |
| Q3 FY2022 | Sep 30, 2022 | -$5.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.95M | – |
| Q4 FY2021 | Dec 31, 2021 | $28.66M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.84M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.24M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.45M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.66M | – |
See a number that looks wrong?